ライフサイエンスコーパス: pleural

1 ofusion, and presence of large opacities and pleural abnormalities.

2 air leakage occurred after the liberation of pleural adhesions.

3 ognitive skills decay at different times for pleural and cardiac images.

4 (TGF-alpha), established by the presence of pleural and peribronchial fibrosis and impaired lung mec

5 y of GATA6(+) macrophages in the peritoneal, pleural and pericardial cavities.

6 eding the gastrointestinal system as well as pleural and peritoneal cavities but not the brain.

7 g woman with a history of previously treated pleural and pulmonary tuberculosis referred to our hospi

8 the pleural cavity, and heightened levels of pleural and serum proinflammatory cytokines and chemokin

9 depth (p = 0.0001) of the lesion, and needle-pleural angle (p = 0.0200).

10 pendicular as possible to the pleura (needle-pleural angle close to 90 degrees ), to minimise the pos

11 nt, size and depth of the lesion, and needle-pleural angle on the incidence of post-procedural pneumo

12 rocedural factors like dwell time and needle-pleural angle was analysed.

13 We report findings from analyses of lung and pleural aspirates collected in the Pneumonia Etiology Re

14 ound and/or polygonal, and irregular shape); pleural attachment was not a significant independent pre

15 e by FALC stromal cells, ILC2 activation and pleural B-cell activation in FALCs, resulting in local a

16 IL-33 produced by FALC stroma is crucial for pleural B1-cell activation and local IgM secretion.

17 rast, CCR5(-/-) mice survived and controlled pleural BCG infection as wild-type control mice.

18 superior to the combination of conventional pleural biomarkers (pH, glucose, and lactate dehydrogena

19 1 tumour proportion score and Ki-67 index in pleural biopsies or cytologies from 123 patients (69 lun

20 y (fluid, biopsy specimen, or sputum) and/or pleural biopsy histopathology (termed definite TB).

21 The patient underwent pleural biopsy, and a diagnosis of T-cell primary pleura

22 omen; 44 patients with cancer with confirmed pleural carcinomatosis and 40 patients with benign pleur

23 uantitative and qualitative determination of pleural carcinomatosis versus noncalcified benign pleura

24 The sensitivities to depict pleural carcinomatosis with spectral reconstructions ver

25 ween noncalcified benign pleural lesions and pleural carcinomatosis.

26 The development of the tunnelled indwelling pleural catheter and ambulatory pleural drainage changed

27 drainage of pleural fluid via an indwelling pleural catheter led to a higher rate of autopleurodesis

28 procedure, and pleural procedure (indwelling pleural catheter vs other).

29 age; n = 76) of pleural fluid via a tunneled pleural catheter.

30 Indwelling pleural catheters allow patients to drain pleural fluid

31 oracotomies, needle biopsies, and indwelling pleural catheters were excluded.

32 is following the placement of the indwelling pleural catheters.

33 tes the pleuroperitoneal folds isolating the pleural cavities before the migration of the somitic myo

34 Monocytes first entered peritoneal or pleural cavities to become MHC II(+) cells that up-regul

35 -derived cells accumulated in peritoneal and pleural cavities, but CD11c(+) CD226(+) macrophages were

36 hat predominantly inhabit the peritoneal and pleural cavities.

37 hysiological cues that activate FALCs in the pleural cavity and more generally the mechanisms control

38 MPM nodules, protruding into the pleural cavity may have growth and spreading dynamics di

39 Plg/Pla injection into the pleural cavity of BALB/c mice induced a time-dependent i

40 r long CNTs or long asbestos fibers into the pleural cavity of mice induces mesothelioma that exhibit

41 lung inflammation, that inflammation of the pleural cavity rapidly activates mediastinal and pericar

42 An injection of carrageenan (CAR) into the pleural cavity triggered an acute inflammatory response,

43 y cell recruitment and bacterial load in the pleural cavity, and heightened levels of pleural and ser

44 e of various human cancers metastatic to the pleural cavity.

45 iotics treatment, which is dependent on both pleural cytokine environment and direct modulatory effec

46 Pleural disseminated, mutant KRAS bearing tumour cells u

47 ns was associated with prolonged post-Fontan pleural drainage (HR, 4.0; P<0.001) and hypoplastic left

48 d indwelling pleural catheter and ambulatory pleural drainage changed the management of malignant ple

49 PCs (13.2% vs 40.5%, P < 0.001), symptomatic pleural effusion (11.6% vs 26.4%, P = 0.003), pleural ef

50 rainage and/or abdominal collections (9.3%), pleural effusion (8.3%), postoperative bleeding (5.6%),

51 Chylous pleural effusion (chylothorax) frequently accompanies ly

52 a (seven [5%]), cholangitis (five [3%]), and pleural effusion (five [3%]).

53 Malignant pleural effusion (MPE) confers dismal prognosis and has

54 Malignant pleural effusion (MPE) is challenging to manage.

55 Malignant pleural effusion (MPE) is the lethal consequence of vari

56 us pleural effusion (TPE, n = 50), malignant pleural effusion (MPE, n = 41), other cases including pn

57 ction (n=1 [2%]), skin infection (n=1 [2%]), pleural effusion (n=1 [2%]), pericardial infusion (n=1 [

58 none), dyspnoea (six [2%] vs one [1%]), and pleural effusion (six [2%] vs none).

59 cancer were thrombocytopenia (eight [11%]), pleural effusion (six [8%]), and increased lipase (five

60 We enrolled 91 cases, including tuberculous pleural effusion (TPE, n = 50), malignant pleural effusi

61 ly pyrexia (four [3%]), and hypertension and pleural effusion (two [1%] each).

62 and in group C, neutropenia (four [6%]) and pleural effusion (two [3%]).

63 he greatest odds of readmission, followed by pleural effusion [OR 7.52 (95% CI, 6.01-9.41)], pneumoth

64 Pleural effusion agreement also differed between pulmona

65 ome features was strong (eg, alpha = .78 for pleural effusion and ascites) but was lower for others (

66 st cancer cells isolated from the metastatic pleural effusion and atypical ductal hyperplasia mammary

67 (one due to pulmonary oedema and one due to pleural effusion and pneumonitis).

68 tial Lobar Collapse, Targeted Physiotherapy, Pleural Effusion assessment, and PEEP optimisation.

69 n in local pulmonary infiltrates group or in pleural effusion group.

70 n 480 (39.5%) patients including symptomatic pleural effusion in 366 (30.1%) patients, respiratory in

71 , central lung involvement, crazy paving and pleural effusion on initial CT chest have potential prog

72 Methods Patients with NSCLC (stage IIIB with pleural effusion or stage IV according to American Joint

73 leural effusion (11.6% vs 26.4%, P = 0.003), pleural effusion requiring drainage (1.7% vs 9.9%, P = 0

74 Pleural effusion was uncommon (2/64, 3%).

75 First occurrences of pleural effusion were reported with dasatinib, with the

76 Subpleural sparing and pleural effusion were seen approximately in one-fifth an

77 Subpleural sparing and pleural effusion were seen in approximately 23% (28/120)

78 tellite nodules, lymph node enlargement, and pleural effusion).

79 arch for thickening of the gallbladder wall, pleural effusion, and ascites.

80 that increased gall bladder wall thickness, pleural effusion, ascites, hepatomegaly, and splenomegal

81 pulmonary infection, aspiration pneumonitis, pleural effusion, atelectasis, cardiopulmonary edema, an

82 Among patients with malignant pleural effusion, daily drainage of pleural fluid via an

83 ever, higher morbidity of tachypnea/dyspnea, pleural effusion, diarrhea, hepatosplenomegaly, consciou

84 With no cure for malignant pleural effusion, efforts are focused on symptomatic man

85 such as severe leakage, fluid accumulation, pleural effusion, gall-bladder wall thickening and rapid

86 drainage changed the management of malignant pleural effusion, not solely by offering an alternative

87 of nine (33.3%) major complications, such as pleural effusion, pneumothoraces or perihepatic hemorrha

88 , pulmonary congestion, respiratory failure, pleural effusion, pneumothorax, or unplanned requirement

89 duration of post-Fontan hospitalization and pleural effusion, postoperative plastic bronchitis, need

90 Among patients with malignant pleural effusion, thoracoscopic talc poudrage, compared

91 stimulation after excluding one patient with pleural effusion.

92 ashimoto thyroiditis and pneumonia with left pleural effusion.

93 ar-interstitial syndrome, consolidation, and pleural effusion.

94 ractory MPP children or in MPP children with pleural effusion.

95 anulomas as well as ascites and a left-sided pleural effusion.

96 nical characters, such as refractoriness and pleural effusion.

97 t upper lobe mass along with a moderate-size pleural effusion.

98 owed mild pulmonary edema with a small right pleural effusion.

99 ations, and one patient with chronic chylous pleural effusion.

100 tion, air bronchogram, nodular opacities and pleural effusion.

101 ctasis or pneumonia on chest radiograph, and pleural effusion.

102 ed pleural thickening coupled with a massive pleural effusion.

103 3 thrombocytopenia, grade 4 neutropenia, and pleural effusion.

104 rs); 12% required intensive care and 26% had pleural effusion.

105 64 [32%] of 200, respectively; P < .001) and pleural effusions (47 [23.5%] of 200 vs 16 [8%] of 200,

106 ping on the rare disseminated tumor cells in pleural effusions across a panel of 32 lung adenocarcino

107 Two patients, including one with large pleural effusions and another with ventricular tachycard

108 n of peritoneal spread, presence and size of pleural effusions and ascites, lymphadenopathy, and dist

109 transfusions, and the presence of bilateral pleural effusions and multi-lobar atelectasis/consolidat

110 gnificantly post antibiotic treatment in the pleural effusions and pleural macrophages up-regulated m

111 le-blind trial involving patients with large pleural effusions at two academic medical centres in, Na

112 values can help in differentiating exudative pleural effusions from transudative pleural effusions.

113 RATIONALE: Patients with malignant pleural effusions have significant dyspnea and shortened

114 L/One hundred and twenty eight patients with pleural effusions on thoracic CT who underwent thoracent

115 entify chylous versus nonchylous ascites and pleural effusions through use of multipoint Dixon fat qu

116 Pleural effusions were classified as exudates or transud

117 effusions.Methods: Patients presenting with pleural effusions were prospectively recruited to an obs

118 Thirty three (26%) of the 128 pleural effusions were transudates and 95 (74%) were exu

119 tomography (CT) findings for characterizing pleural effusions with the use of attenuation values.

120 ew-onset heart failure symptoms or recurrent pleural effusions within 2 years of lung transplantation

121 Regarding the detection of pleural effusions, there was no significant performance

122 lator-associated pneumonia, atelectasis, and pleural effusions.

123 xudative pleural effusions from transudative pleural effusions.

124 atients presented with worsening dyspnea and pleural effusions.

125 iation of chylous and nonchylous ascites and pleural effusions.

126 thoracic notum as well as the already known pleural elements of the arthropodan leg.

127 ax after a thoracic drainage procedure for a pleural empyema) in the ramucirumab plus erlotinib group

128 tures that were evaluated for distinguishing pleural exudates from transudates included pleural nodul

129 ased numbers of apoptotic neutrophils in the pleural exudates, inhibition of elastase, and modulation

130 d target for amelioration of empyema-related pleural fibrosis and provide a strong rationale for furt

131 In pleural fibrosis excess collagen deposition results in p

132 an resolve with restrictive lung disease and pleural fibrosis.

133 lier age that was more often peritoneal than pleural (five of nine) and exhibited improved long-term

134 Percutaneous trans-thoracic lung (LA) and pleural fluid (PF) aspiration was performed on a sample

135 -wide transcriptomic study, we observed that pleural fluid (PF), an HSA-containing fluid, increases D

136 Pleural fluid and serum suPAR levels were measured using

137 ng pleural catheters allow patients to drain pleural fluid at home and can lead to autopleurodesis.

138 atients with non-expandable lung, removal of pleural fluid can result in excessively negative pleural

139 dentified from lung aspirate culture or PCR, pleural fluid culture or PCR, blood culture, and immunof

140 e blood culture or positive lung aspirate or pleural fluid culture or polymerase chain reaction [PCR]

141 Pleural fluid cytology was positive for adenocarcinoma.

142 cultures and molecular testing, including on pleural fluid if a drainage procedure is done.

143 s discontinued before complete evacuation of pleural fluid if patients developed persistent chest dis

144 cases with radiological consolidation and/or pleural fluid in 4 countries.

145 current standard every other day drainage of pleural fluid in achieving autopleurodesis.

146 ctivator receptor), a potential biomarker of pleural fluid loculation, to predict the need for invasi

147 For decades, physicians have relied on pleural fluid pH to determine the need for chest tube dr

148 ULTRA performance outcomes were evaluated in pleural fluid samples from 149 patients with suspected p

149 ainage (every other day drainage; n = 76) of pleural fluid via a tunneled pleural catheter.

150 alignant pleural effusion, daily drainage of pleural fluid via an indwelling pleural catheter led to

151 Ultimately, the combination of pleural fluid with the plasma tuberculosis-specific IL-3

152 = 41), other cases including pneumonia with pleural fluid, pulmonary tuberculosis and healthy people

153 rom those with radiological consolidation or pleural fluid, with S. pneumoniae and S. aureus the lead

154 on, ground glass opacity (GGO), location and pleural fluid.

155 ween sputum, lung samples, chest wounds, and pleural fluid.

156 evels of instability observed in ascites and pleural fluid.

157 d to assess the lung parenchyma, to identify pleural fluid; CT scanning is not usually indicated.

158 gamation of elements from both the notal and pleural hypotheses.

159 For pleural image acquisition, there was no significant decl

160 sessions related to image identification for pleural images, and more hands-on image acquisition trai

161 BCG-induced pleural infection was uncontrolled and progressive in ab

162 Pleural injection of Plg/Pla also increased M2 markers (

163 gen activator and plasmin) are elaborated in pleural injury and strongly induce MesoMT in vitro.

164 nistration of 9ING41, after the induction of pleural injury, attenuated injury progression and improv

165 3beta signaling in the control of MesoMT and pleural injury.

166 Gy in three fractions within 42 days of the pleural intervention) or deferred radiotherapy (same dos

167 en mesothelioma who had undergone large-bore pleural interventions in the 35 days prior to recruitmen

168 provided weak evidence to rule out visceral pleural invasion (positive LR, 0.38).

169 the accuracy of early diagnosis of visceral pleural invasion by NSCLC that does not abut the pleura.

170 patients (44 patients [31.2%] with visceral pleural invasion proved by pathologic analysis and 97 pa

171 In the absence of pleural tags, no pleural invasion was found.

172 tags was moderately associated with visceral pleural invasion with the following results: positive LR

173 gic analysis and 97 patients [68.8%] without pleural invasion) was conducted at a single tertiary cen

174 Measurement of cytokines from the pleural lavage showed that mice implanted with MPM cells

175 tment; after 6 more months of treatment, the pleural lesion and chest pain disappeared.

176 ained by US-guided fine-needle biopsy of the pleural lesion were positive for Mycobacterium tuberculo

177 differentiation between noncalcified benign pleural lesions and pleural carcinomatosis.

178 status of this key tumor suppressor gene in pleural lesions preceding mesothelioma.

179 and/or imaging confirmation of noncalcified pleural lesions were evaluated.

180 l carcinomatosis and 40 patients with benign pleural lesions).

181 al carcinomatosis versus noncalcified benign pleural lesions.

182 tifocal spread thickening of the pleura with pleural line irregularities (70%), confluent B lines (60

183 Pleural loculation affects about 30,000 patients annuall

184 Pleural lymphoma is a medical condition characterised by

185 Pleural lymphoma is a rare diagnosis especially in child

186 al biopsy, and a diagnosis of T-cell primary pleural lymphoma was made.

187 maging and was diagnosed with T-cell primary pleural lymphoma, a very rare subtype of primary pleural

188 ral lymphoma, a very rare subtype of primary pleural lymphoma.

189 Here, we examined whether and how pleural macrophages change in phenotype, transcription a

190 ic genes could be used to study the roles of pleural macrophages in the pathogenesis of tuberculous p

191 nes was modulated directly by antibiotics in pleural macrophages in vitro.

192 Pleural macrophages play critical roles in pathogenesis

193 Our results conclude that pleural macrophages polarize from M1-like to M2-like phe

194 iotic treatment in the pleural effusions and pleural macrophages up-regulated markers characteristic

195 d 230 treatment-specific responsive genes in pleural macrophages.

196 Pleural malignant mesothelioma is a therapy-resistant ca

197 Pleural manometry is widely used to safeguard against pr

198 were analysed based on parenchymal, airway, pleural, mediastinal, and vascular sequelae of PTB.

199 ) containing vesicle transportation in human pleural mesothelial cells (HPMCs).

200 ough increased phosphorylation of Tyr-216 in pleural mesothelial cells and GSK-3beta mobilization fro

201 Pleural mesothelial cells contribute to pleural rind for

202 ype was highly significant for patients with pleural mesothelioma (median survival 7.9 y versus 2.4 y

203 Malignant pleural mesothelioma (MPM) has an overall poor prognosis

204 peutic procedures in patients with malignant pleural mesothelioma (MPM) has been a widespread practic

205 Malignant pleural mesothelioma (MPM) is a highly aggressive and ge

206 Malignant pleural mesothelioma (MPM) is a rare, but aggressive tum

207 Malignant pleural mesothelioma (MPM) is an aggressive cancer that

208 Malignant pleural mesothelioma (MPM) is an aggressive human cancer

209 Malignant pleural mesothelioma (MPM) is an aggressive malignancy a

210 Hemithoracic IMPRINT for malignant pleural mesothelioma (MPM) is safe and has an acceptable

211 ed in patients with ASS1-deficient malignant pleural mesothelioma (MPM) or non-small-cell lung cancer

212 targeted exomes (n = 103) from 216 malignant pleural mesothelioma (MPM) tumors.

213 therapy as first-line treatment of malignant pleural mesothelioma (MPM).

214 ured tumor volume in patients with malignant pleural mesothelioma (MPM).

215 y in the treatment of unresectable malignant pleural mesothelioma (MPM).

216 rgoing cancer-directed surgery for malignant pleural mesothelioma (MPM); however, it is unclear if th

217 ars) with unresectable epithelioid malignant pleural mesothelioma and ECOG performance status 0-1 wer

218 ere on the interim analysis of the malignant pleural mesothelioma cohort.

219 , every 3 wk) for the treatment of malignant pleural mesothelioma did not result in survival benefit

220 Malignant pleural mesothelioma is a highly aggressive cancer with

221 sed immunotherapy in patients with malignant pleural mesothelioma is feasible, well-tolerated, and ca

222 ria In Solid Tumors (RECIST) version 1.0 for pleural mesothelioma or RECIST version 1.1 for peritonea

223 nases, which are all implicated in malignant pleural mesothelioma pathogenesis.

224 ocedure-tract metastases (PTMs) in malignant pleural mesothelioma remains controversial, and clinical

225 port on their use of a murine model of human pleural mesothelioma to explore potential factors that l

226 eated patients with PD-L1-positive malignant pleural mesothelioma were enrolled from 13 centres in si

227 Patients with pleural mesothelioma with inherited mutations in DNA rep

228 al from malignant mesothelioma, particularly pleural mesothelioma, is very poor.

229 Using an orthotopic mouse model of pleural mesothelioma, we determined that relatively high

230 tedanib or placebo in unresectable malignant pleural mesothelioma.

231 ed 68 with advanced ASS1-deficient malignant pleural mesothelioma.

232 ty in patients with PD-L1-positive malignant pleural mesothelioma.

233 on in patients with ASS1-deficient malignant pleural mesothelioma.

234 Pleural mesothelium overlying the lymphatic plexuses und

235 cic cavity through exfoliated regions of the pleural mesothelium.

236 In ES with pulmonary or pleural metastases, there is no clear benefit from BuMel

237 arcoma (ES) presenting with pulmonary and/or pleural metastases.

238 ewly diagnosed ES and with only pulmonary or pleural metastases.

239 Here we show, using separate models of pleural nematode infection with Litomosoides sigmodontis

240 to our hospital for chest pain and a single pleural nodule seen on plain chest films and chest CT.

241 date patients in terms of pleural thickness, pleural nodules and loculation (p>0.05).

242 g pleural exudates from transudates included pleural nodules, pleural thickening and loculation.

243 The parietal pleural of TNF(-/-) and TNFR1R2(-/-) mice exhibited abun

244 re defined by the presence of fetal ascites, pleural or pericardial effusions, skin edema, cystic hyg

245 s 19 countries in patients with unresectable pleural or peritoneal malignant mesothelioma who had pro

246 arly in 9 of 41 patients in the PD group for pleural-peritoneal communication.

247 onfidence interval, 0.89-0.98) compared with pleural pH (AUC 0.82; 95% confidence interval, 0.73-0.90

248 e proliferation of primary cultures of human pleural (Pl) MM, implicating nonepithelioid histology an

249 jectives: To define the relationship between pleural plaques and lung cancer risk.

250 Pleural plaques did not confer any additional lung cance

251 Conclusions: The presence of pleural plaques on radiologic imaging does not confer ad

252 tion between lung cancer and the presence of pleural plaques remains controversial.

253 , 3,486 (82.0%) were male, 1,315 (31.0%) had pleural plaques, and 1,353 (32.0%) had radiographic asbe

254 bestos exposure, presence of asbestosis, and pleural plaques.

255 Surgery for MPM has shifted from extra-pleural pneumonectomy to PDC with the goal of MCR.

256 ionale: Obesity is characterized by elevated pleural pressure (P(PL)) and worsening atelectasis durin

257 Measurement of pleural pressure by manometry during large-volume thorac

258 ive end-expiratory pressure (PEEP) to offset pleural pressure might attenuate lung injury and improve

259 criterion for stopping was if end-expiratory pleural pressure was lower than -20 cm H(2)O or declined

260 We investigated whether monitoring of pleural pressure with manometry during thoracentesis cou

261 ral fluid can result in excessively negative pleural pressure, which is associated with chest discomf

262 oing mechanical ventilation due to increased pleural pressure.

263 surgical versus non-surgical procedure, and pleural procedure (indwelling pleural catheter vs other)

264 enic pneumothoraces while performing bedside pleural procedures has increased but with little underst

265 e safety of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) after chemotherapy a

266 fic-related black carbon accumulation in the pleural region and in lymph).

267 Pleural mesothelial cells contribute to pleural rind formation by undergoing mesothelial mesench

268 Pleural sequelae included pleural thickening (22%), with

269 oracic notum as well as the expected medial, pleural series of axillary sclerites.

270 Information from pleural space imaging and drainage should guide the deci

271 instillation of a sclerosant agent into the pleural space to achieve pleurodesis.

272 eloid cells from the host bone marrow to the pleural space via the spleen.

273 Pleural suPAR could more accurately predict the subseque

274 nt effusions).Measurements and Main Results: Pleural suPAR levels were significantly higher in effusi

275 gery (AUC 0.92 vs. 0.76).Conclusions: Raised pleural suPAR was predictive of patients receiving more

276 n significantly decreases away from the lung pleural surface (p < 0.001, n = 25 and p < 0.01, n = 20,

277 The ablation zone extended to the pleural surface adjacent to the heart in 71% of parallel

278 higher when those patterns not reaching the pleural surface were excluded (area under the receiver o

279 ifference between the alveolar space and the pleural surface), traditionally known as the "elastic re

280 the opening to the pulmonary airway and the pleural surface).

281 Type 2 pleural tags on conventional CT images can increase the

282 Type 1 pleural tags provided weak evidence to rule out visceral

283 The presence of type 2 pleural tags was moderately associated with visceral ple

284 In the absence of pleural tags, no pleural invasion was found.

285 tive performance of newer same-day tools for pleural TB, including Xpert MTB/RIF Ultra (ULTRA), has h

286 RA has poor sensitivity for the diagnosis of pleural TB.

287 uid samples from 149 patients with suspected pleural TB.

288 Pleural sequelae included pleural thickening (22%), with 40.9% of these patients s

289 s from transudates included pleural nodules, pleural thickening and loculation.

290 X-ray and CT scan, which showed right sided pleural thickening coupled with a massive pleural effusi

291 with Col-1 and alpha-smooth muscle actin in pleural thickening in the carbon-black bleomycin mouse m

292 Pleural thickening was also notably reduced in 9ING41-tr

293 brosis excess collagen deposition results in pleural thickening, increased stiffness and impaired lun

294 imal pleural thickness (P (max)) and average pleural thickness (P (avg)) on axial MR images; maximal

295 Unidimensional measurements of maximal pleural thickness (P (max)) and average pleural thicknes

296 transudate and exudate patients in terms of pleural thickness, pleural nodules and loculation (p>0.0

297 The diagnosis of pleural tuberculosis (TB) is problematic.

298 n (n=2), inability to access effusion due to pleural tumour burden (n=1), and inability to remain sea

299 For pleural ultrasound by 4 weeks, there was a significant d

300 cond line vs third line), and anatomic site (pleural vs peritoneal), by use of an interactive voice o